AMRX (Amneal Pharmaceuticals) Capital Expenditure : $-73.55 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Amneal Pharmaceuticals's cash flow for capital expenditures for the three months ended in Mar. 2025 was $-18 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was $-73.55 Mil.

Amneal Pharmaceuticals Capital Expenditure Historical Data

The historical data trend for Amneal Pharmaceuticals's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals Capital Expenditure Chart

Amneal Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Capital Expenditure

Get a 7-Day Free Trial

-66.19

-52.64

-90.60

-69.19

-74.99

Amneal Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Capital Expenditure	Get a 7-Day Free Trial															-19.76	-11.45	-20.71	-23.06	-18.32

Amneal Pharmaceuticals Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.55 Mil.

Amneal Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (NAS:AMRX) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807

Website

https://www.amneal.com

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Executives

Nikita Shah	officer: SVP, Chief HR Officer	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
John Kiely	director	C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286
Gautam Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Tushar Bhikhubhai Patel	10 percent owner	C/O TARSADIA INVESTMENTS, 520 NEWPORT CENTER DRIVE, 21ST FLOOR, NEWPORT BEACH CA 92660
Andrew S Boyer	officer: Exec VP, Comm Optns	C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960
Tasos Konidaris	officer: SVP and CFO	103 JFK PARKWAY, SHORT HILLS NJ 07078
Deborah M. Autor	director	C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Jason B. Daly	officer: SVP, Chief Legal Officer	400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807
Tpg Gp A, Llc	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Gustavo Pesquin	officer: See Remarks	4 PARK LANE, MADISON NJ 07940
Jon Winkelried	10 percent owner	C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Chirag K. Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Chintu Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807
Joseph Todisco	officer: SVP, Specialty Commercial	400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Jeffrey P. George	director	C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807